Stoke Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Stoke Therapeutics possède un total de capitaux propres de $232.1M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $293.3M et de $61.2M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$239.20m
Fonds propres	US$232.11m
Total du passif	US$61.21m
Total des actifs	US$293.32m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 0GT ( $253.6M ) dépassent ses passifs à court terme ( $49.9M ).

Passif à long terme: Les actifs à court terme de 0GT ( $253.6M ) dépassent ses passifs à long terme ( $11.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 0GT est sans dette.

Réduire la dette: 0GT n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 0GT dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 0GT dispose d'une marge de trésorerie suffisante pour 1.8 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 23.4 % chaque année.

Stoke Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.47 loss per share (vs US$0.55 loss in 3Q 2023)

Stoke Therapeutics, Inc. Appoints Eric Olson as Chief Business Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.46 loss per share (vs US$0.69 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.57 loss per share (vs US$0.53 loss in 1Q 2023)

Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024

Stoke Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000004 million.

Stoke Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000005 million.

Stoke Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: US$2.38 loss per share (vs US$2.60 loss in FY 2022)

New major risk - Share price stability

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.55 loss per share (vs US$0.66 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Stoke Therapeutics, Inc. Appoints Ian Smith to Board of Directors

Stoke Therapeutics, Inc. Presents Data Related to the Ongoing Clinical Development of Stk-001 for the Treatment of Dravet Syndrome

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$0.63 loss in 2Q 2022)

New major risk - Revenue and earnings growth

Stoke Therapeutics, Inc. Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (Monarch & Adolescents with Dravet Syndrome

Insufficient new directors

Stoke Therapeutics, Inc. Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

High number of new directors

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell 2000 Growth Index

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and Opa1 Protein Upregulation in Retinal Tissue Following Administration of Stk-002

High number of new directors

Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome

Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

New 90-day high: €52.50

New 90-day high: €46.00

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

Stoke Therapeutics, Inc. Announces Resignation of Robin A. Walker, Senior Vice President, Chief Legal Officer and Chief Compliance Officer

New 90-day high: €34.20

New 90-day high: €32.20

Stoke Therapeutics, Inc. Announces Plans to Move Forward with Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a Monarch Study for Dravet Syndrome

New 90-day high - €26.80

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines